Colitis ulcerosa nebenwirkungsarm therapierenE. coli Nissle 1917 und Mesalazin zur Remissionserhaltung äquivalent wirksam

Abstract: Several studies have shown that treatment with viable indigenous E. coli may protect against relapse in ulcerative colitis. A clinical trial conducted in Leeds, England, was designed to determine whether treatment with E. coli strain Nissle 1917 is equally effective in maintaining remission as mesalazine.116 patients with active ulcerative colitis were recruited and were given standard medical therapy with steroids and a one week course of oral gentamicin. In addition they were randomized to receive either mesalazine or E. coli strain Nissle 1917 (MutaflorTM). After remission had been attained, steroid treatment was withdrawn, whereas treatment with mesatazine or MutaflorTM was continued during a 12-months follow-up.In the mesalazine group, 73% of patients relapsed during the one year follow-up compared with 67% in the E. coli group. The median duration of remission was 175 days in the mesalazine group compared with 185 days in the group given E. coli.The results suggest that treatment with E. coli strain Nissle 1917 has an equivalent effect to mesalazine in maintaining remission.

Keyword(s): Chronisch entzündliche Darmerkrankungen

Zurück | Weiter